Controversy and Change: FDA Chief's Resignation Unfolds Amid Pressure

Marty Makary, U.S. FDA Commissioner, plans to resign amid criticism over policy decisions and leadership challenges. His departure follows mounting pressure from political groups, media, and the Trump administration. Kyle Diamantas will temporarily lead the agency. Controversies included disagreements over drug approvals and reintroducing flavored vapes.

Marty Makary, who has served as the U.S. Food and Drug Administration Commissioner since March, is set to resign, sources revealed on Tuesday. Speculation of his departure and mounting pressure have been prevalent in recent weeks, compounded by a reported directive from President Trump to remove him.

Makary faced criticism for decisions around drug approvals, handling of flavored vapes, and vaccine mandates. Discontent with his leadership came from various sectors, including conservatives, pharmaceutical companies, and anti-abortion factions. As a result, Kyle Diamantas will assume an acting leadership role at the FDA.

The Wall Street Journal editorial board was a vocal critic, showcasing articles that targeted Makary's rejections of certain drugs, such as a melanoma therapy from Replimune. During his tenure, the FDA saw multiple leadership changes within its vaccine division, in what has been described as a turbulent period for the agency.